SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

About this update from Sab Biotherapeutics, Inc.

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetesStrong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activitiesConference call today at 8:30 AM ETMIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced financial results for the first quarter ended March 31, 2026, and provided recent business highlights. “The first quarter set a strong foundation for the year, as we executed according to plan across all fronts.  I am encouraged to report that SAFEGUARD enrollment is progressing on schedule for completion by year-end.  Our Phase 1 data demonstrate early C-peptide preservation and improved glycemic control with a favorable safety profile, and our recent public offering bolsters our financial runway through 2028 to support this program and pre-commercial activities,” said Samuel J. Reich, Chief Executive Officer of SAB BIO. “This year we are focused on enrolling SAFEGUARD with Part A fully enrolled and Part B well underway and proceeding as planned. The pace of enrollment and enthusiasm from investigators underscores the urgent need within the diabetes community for therapies that go beyond insulin management to address the underlying autoimmune disease.”Recent Pipeline Achievements and Anticipated Milestones for SAB-142Phase 2b SAFEGUARD studyContinued activation of multiple clinical trial sites in U.S., Australia, New Zealand, U.K. and European Union for SAFEGUARD (SAFety and Efficacy of human anti-thymocyte immunoGlobUlin SAB-142 ARresting progression of type 1 Diabetes) trial.The SAFEGUARD trial will enroll a total of 159 Stage 3 T1D patients (ages 5-40), within 100 days of diagnosis. Part A is a dose-ranging study in 12 adult T1D patients and has completed enrollment during the first quarter.Part B is a randomized, double-blind, placebo-controlled, do...

View stock analysis, news, and events for Sab Biotherapeutics, Inc.